Your new experience awaits. Try the new design now and help us make it even better

ORIGINAL RESEARCH article

Front. Oncol.

Sec. Genitourinary Oncology

Muscle size and muscle fat infiltration in patients with newly diagnosed prostate cancer: a case-control study

Provisionally accepted
Chao  WangChao Wang1Hui  WangHui Wang1Yufei  YuYufei Yu1Xinming  YangXinming Yang1Yu  WangYu Wang2Kui  ZhangKui Zhang1Shuangquan  SunShuangquan Sun1Lingfeng  WuLingfeng Wu1Daocheng  FangDaocheng Fang1Hui  LiHui Li1Yi  YangYi Yang1Xiao  ChenXiao Chen2*Shumei  BiShumei Bi1*Hui  WenHui Wen1*
  • 1Songjiang Hospital Affiliated to Shanghai Jiao Tong University School of Medicine, Shanghai, China
  • 2Affiliated Hospital of Nanjing University of Chinese Medicine, Nanjing, China

The final, formatted version of the article will be published soon.

Aims Cancer is a recognized risk factor for sarcopenia. While some studies suggest that androgen deprivation therapy (ADT) may contribute to muscle loss in patients with prostate cancer (PCa), it remains unclear whether alterations in muscle composition are already present at the initial diagnosis, before any treatment begins. This study aimed to evaluate computed tomography (CT)–based muscle size and muscle fat infiltration in patients with newly diagnosed prostate cancer. Methods A total of 143 patients with newly diagnosed PCa (January 2023–June 2024) were enrolled and matched 1:2 with 286 controls. CT attenuation and crosssectional area of the erector spinae (ES) and fulllayer muscle at the T12 level were measured. The muscletospleen attenuation ratio (M/S) was calculated. Muscle fat infiltration was assessed based on muscle CT attenuation. Multivariable logistic regression analyses were performed to examine the association between PCa and the risk of low muscle CT attenuation or low muscle area. Results In PCa patients, muscle CT attenuation, M/S ratio, ES area, and fulllayer muscle area decreased with advancing age. Overall, muscle CT attenuation and M/S ratio were significantly lower in the PCa group than in controls. Both ES area and fulllayer muscle area were also significantly reduced in PCa patients younger than 70 years. A similar difference in ES area was observed in the 70–80year age group. After full adjustment, PCa was significantly associated with an increased risk of low ES CT attenuation (OR = 2.59, 95% CI: 1.25–5.39), low fulllayer muscle CT attenuation (OR = 7.14, 95% CI: 3.30–15.45), low fulllayer muscle M/S ratio (OR = 4.29, 95% CI: 2.01–8.87), and low ES area (OR = 2.94, 95% CI: 1.33–6.53). Similar associations were observed in the nondiabetic subgroup. Conclusion Newly diagnosed prostate cancer is associated with an increased risk of CTbased skeletal muscle fat infiltration and reduced muscle area.

Keywords: case-control, Muscle fat infiltration, Muscle size, prostate cancer, Sarcopenia

Received: 18 Sep 2025; Accepted: 09 Feb 2026.

Copyright: © 2026 Wang, Wang, Yu, Yang, Wang, Zhang, Sun, Wu, Fang, Li, Yang, Chen, Bi and Wen. This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) or licensor are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.

* Correspondence:
Xiao Chen
Shumei Bi
Hui Wen

Disclaimer: All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article or claim that may be made by its manufacturer is not guaranteed or endorsed by the publisher.